TrialThe Lancet. Oncology2021

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

Thomas Powles et al.PubMed ↗Publisher ↗

No numbers read from the abstract.